-
HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases
•
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot firm SSY Group Ltd. (HKG: 2005). The collaboration aims to integrate HighTide’s unique strengths in the multi-system collaborative innovation of natural products with SSY’s extensive experience in activity screening, formulation development, achievement transformation, quality control,…
-
HighTide Therapeutics Completes Enrollment for Two Phase III Trials of T2DM Drug Candidate HTD1801
•
HighTide Therapeutics Inc., (HKG: 2511), a biopharmaceutical company based in China, has announced the completion of patient enrollment for two Phase III clinical studies of its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) for the treatment of type 2 diabetes (T2DM). The studies include the multi-center, randomized, double-blind, placebo-controlled SYMPHONY-1, which…
-
HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province
•
HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made its debut on the Hong Kong Stock Exchange, is set to broaden its business operations to encompass Hebei province. This strategic move follows the company’s successful listing last month and aims to strengthen its presence…
-
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
•
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange this week. The company issued 24 million shares, each priced at HKD 11.5, resulting in a net proceeds amount of HKD 194.1 million (USD 25 million). Founded…
-
HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study
•
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) as a treatment for type 2 diabetes (T2DM) has achieved its primary endpoint and several important secondary endpoints. The study demonstrated that treatment with HTD1801 resulted in a superior…
